Sensorion announces that the Company’s shareholders are invited to participate in the Combined General Meeting, to be held on Wednesday, May 24, 2023, at 2 pm CET in the premises of the hotel Square Louvois, located at 12, rue de Louvois, 75002, Paris, France.
IRLAB Therapeutics AB announced that IRLAB has been made aware that Ipsen’s 2022 Universal Registration Document, published on April 6, 2023, contains incorrect information that the development and commercialization rights for mesdopetam have been transferred back to IRLAB.
Occlutech Holding AG is a leading specialist provider of minimally invasive structural heart implants.
IRLAB Therapeutics AB announced that the company will hold a presentation in conjunction with the publication of the interim report for the period January-March 2023.
IRLAB: Invitation to the Interim Report for Q1 2023 Presentation and Webcast Read More »
Innate Pharma SA, announced that the Company will hold a conference call on Wednesday, May 10, 2023 at 2 p.m. CEST / 8 a.m. EDT, to give an update on business progress during the first quarter of 2023.
Innate Pharma Announces Conference Call and Webcast for Q1 Business Update Read More »
Lannett Company, Inc. announced that it and certain of its subsidiaries have commenced prepackaged Chapter 11 cases in the United States Bankruptcy Court for the District of Delaware to effectuate the transactions contemplated by the Restructuring Support Agreement announced on May 1, 2023.
Skyline Therapeutics announced multiple data presentations at the American Society of Gene and Cell Therapy 26th Annual Meeting in Los Angeles, CA, May 16-20, 2023.
Skyline Therapeutics to Present at the ASGCT 26th Annual Meeting Read More »
Adagio Medical, Inc., a leading innovator in catheter ablation technologies for atrial fibrillation and ventricular tachycardia, announced the completion of enrollment in its Cryocure-VT trial of ultra-low temperature cryoablation for the treatment of monomorphic ventricular tachycardias.
Hyundai Bioscience announced on the 28th that it had received the clinical study report for the COVID-19 phase 2 clinical trial of its antiviral drug ‘Xafty’.
In addition to promoting their brands, companies say their funding initiatives give them access to the expertise of top researchers and contribute to society.
Industry Seeks to Stimulate Innovation Through Grant Programs Read More »
